Zobrazeno 1 - 10
of 89
pro vyhledávání: '"S Fernández Peña"'
Autor:
S Izquierdo Muñoz, MT Sánchez Sánchez, M Izquierdo Navarro, S Fernández Peña, ME Cárdaba García
Publikováno v:
Eur J Hosp Pharm
Background The implementing Law 1015/2009 normalises the compassionate use of investigational drugs, access to off-label and unauthorised drugs in Spain. Rituximab is an anti-CD20 monoclonal antibody widely used in off-label conditions to treat autoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4832581c240fcffc96280a6d9ab5fc74
https://europepmc.org/articles/PMC7535219/
https://europepmc.org/articles/PMC7535219/
Publikováno v:
European Journal of Hospital Pharmacy. 23:A224.1-A224
Background Aromatase inhibitors (AI) are used in postmenopausal women for adjuvant treatment of hormone receptor positive breast cancer. AI led to profound oestrogen suppression and may be expected to increase the risk of carpal tunnel syndrome (CTS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f5c9f3cd197740fb9599902f1aa2e18
https://doi.org/10.1136/ejhpharm-2016-000875.507
https://doi.org/10.1136/ejhpharm-2016-000875.507
Publikováno v:
European Journal of Hospital Pharmacy. 23:A127.1-A127
Background Simeprevir, sofosbuvir and daclatasvir are new drugs for the treatment of hepatitis C virus (HCV) and are apparently safer than preceding treatments. Due to the limited patient profiles in clinical trials as well as limited length, adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9f4cf83595549c5827e04b5abf1dbe2
https://doi.org/10.1136/ejhpharm-2016-000875.288
https://doi.org/10.1136/ejhpharm-2016-000875.288
Autor:
M Etxeberria Uriz, Pérez Fernández, S Fernández Peña, R Juanbeltz Zurbano, M de Miguel Gaztelu, B Tirapu Nicolás
Publikováno v:
European Journal of Hospital Pharmacy. 23:A229.1-A229
Background Complementary and alternative medicine (CAM) use has grown considerably, although there is little research about its prevalence in cancer patients in Europe. Purpose The main objective of this study was to determine the prevalence of CAM u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3d606239be2e2b139c05223b9ab43fc
https://doi.org/10.1136/ejhpharm-2016-000875.519
https://doi.org/10.1136/ejhpharm-2016-000875.519
Publikováno v:
European Journal of Hospital Pharmacy. 23:A87.3-A88
Background Sepsis is a disease with an increasing prevalence and high hospital mortality rates. A hospital Multidisciplinary Working Group on Sepsis Code was created with the mission of implementing and developing clinical management guidelines to fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35b3f7fc6d99658ed9a5de45ce51a460
https://doi.org/10.1136/ejhpharm-2016-000875.198
https://doi.org/10.1136/ejhpharm-2016-000875.198
Autor:
M Izquierdo Navarro, S Fernández Peña, A Salvador Palacios, S Izquierdo Muñoz, ME Cárdaba García
Publikováno v:
European Journal of Hospital Pharmacy. 23:A15.1-A15
Background Mercaptopurine is indicated for the treatment of acute lymphoblastic leukaemia (ALL). In our country, there is no commercial presentation that allows proper dosage in paediatric patients. However, in March 2012, an expensive 20 mg/mL merca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d907075a98600af55260c390776ebd6b
https://doi.org/10.1136/ejhpharm-2016-000875.34
https://doi.org/10.1136/ejhpharm-2016-000875.34
Autor:
M Hernando Verdugo, J Varela González-Aller, T Sánchez Sánchez, ME Cárdaba García, S Fernández Peña, S. Camacho Parreño
Publikováno v:
European Journal of Hospital Pharmacy. 23:A15.2-A16
Background Antiangioagenic drugs, ranibizumab, bevacizumab and the most recent one marketed, aflibercept, are the elected treatments of age related macular degeneration (AMD). These treatments are a heavy economic burden because of the growing number
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5276863afe613b1f9b52109442283338
https://doi.org/10.1136/ejhpharm-2016-000875.35
https://doi.org/10.1136/ejhpharm-2016-000875.35
Autor:
A.M. López González, V Cabezas Martín, ME Cárdaba García, J Varela González-Aller, T Sánchez Sánchez, S Fernández Peña
Publikováno v:
European Journal of Hospital Pharmacy. 23:A63.3-A64
Background Levosimendan is a positive inotropic drug that was approved in our country for the short term treatment of acute decompensation in chronic heart failure in situations where conventional treatment is not sufficient. There are few studies on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::30a97e89ea1d407a8a68dbc8ba6e66f7
https://doi.org/10.1136/ejhpharm-2016-000875.144
https://doi.org/10.1136/ejhpharm-2016-000875.144
Publikováno v:
European Journal of Hospital Pharmacy. 23:A198.3-A199
Background Commercial presentations of oral thioguanine suitable for dosing in paediatric patients diagnosed with acute lymphoblastic leukaemia (ALL) are not available in our country. Therefore, paediatricians in our hospital requested the pharmacy d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da849fa792802850ffa4c05da77e69cf
https://doi.org/10.1136/ejhpharm-2016-000875.449
https://doi.org/10.1136/ejhpharm-2016-000875.449
Publikováno v:
European Journal of Hospital Pharmacy. 22:A95.1-A95
Background Reactivation of hepatitis B virus (HBV) is a well-recognised complication in patients with chronic HBV infection who receive cytotoxic or immunosuppressant treatment. Patients undergoing rituximab treatment should be checked routinely for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c0dc3ae1ee1c45ecfa1df081e77144c
https://doi.org/10.1136/ejhpharm-2015-000639.228
https://doi.org/10.1136/ejhpharm-2015-000639.228